However, in patients with non-small cell lung cancer, high serum antibody against NY-ESO-1 and XAGE-1 levels were associated with higher efficacy of anti-PD-1 antibody therapy but did not correlate with the intensity of NY-ESO-1 and XAGE-1 immunostaining (17). Here, CTAG1B is linked to non-small cell lung carcinoma.